article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

The documents state that a partnership with a CMO would be cheaper than the state directly manufacturing insulin. California’s budget documents give few details about the tender process, but state that CalRx will spend $50 million to partner with a contract manufacturer to develop biosimilar insulin products in vial and pen form.

Insurance 131
article thumbnail

The Inflation Reduction Act: The Impact of Medicare Negotiation of Prescription Drug Prices on Hospitals and Health Systems

Omnicell

In 2029 and each year after, 20 drugs from Part D or Part B will be added. The number of drugs with MFPs set will increase by 15 in 2027 (all from Part D) to 25 in total. In 2028, 15 drugs from Part D or Part B (combined) will be added, resulting in a total of 40 drugs with MFPs set. ” Sen. John Barrasso (R-Wyo.)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Highlights from ESCMID Global 2024: AI, climate change and AMR

Hospital Pharmacy Europe

In microbiologically documented HAIs, 32% of microorganisms were resistant to antimicrobials. The ECDC report was published in the same week that the UK Government released its new policy paper ’ Confronting antimicrobial resistance 2024 to 2029 ’, which sets out its latest five-year national action plan to support its 20-year vision for AMR.

article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

The FDA Law Blog

Although the program has not been without its critics (including as documented in two GAO reports from 2016 and 2020 ), there is ample evidence that the program has been successful at accomplishing its goals, which has become more evident with time.